Nextera is a biotechnology company based on a proprietary new phage display technology. The company develops pharmaceuticals targeting autoimmune, cancer and infection diseases through unique new drug targets. Nextera utilizes the pVII capsid protein of filamentous bacteriophages as a scaffold for display of peptides and proteins. The technology fosters easy display of two different proteins on the very same phage particle, thus gaining new functionality to existing phage display systems. Nextera is based on technology from the inventor Geir Åge Løset who has been part of the internationally renowned group of Professor Inger Sandlie at the University of Oslo. Sandlie’s group is one of the pioneers in the field of antibody engineering with articles in highly rated journals such as Nature, Nature reviews in drug discovery and PNAS etc. The company has the vision to be a leading source of new drug targets and drug candidates for autoimmune and cancer diseases. In 2015 Nextera made a R&D collaboration agreement with Jansen within rheumatoid arthritis. Birk Venture made the first investment in 2010 and is chairing the Board of the Directors of the Company. Go to website Back to menu
Location: Norway, Oslo